Get started
Author

Kelley Coffman

Observed names: K. Coffman, Kelley Coffman D'Annibale, Kelley Coffman-D'Annibale, Kelley Coffman-D’Annibale, Kelley L. Coffman, Kelley L. Coffman D’Annibale, Kelley L. Coffman‐D'Annibale, Kelley L. Coffman‐D’Annibale, Kelley Lauren Coffman
Observed institutions: National Institutes of Health, Memorial Sloan Kettering Cancer Center, NYU Langone Health, National Cancer Institute, Center for Cancer Research, Georgetown Lombardi Comprehensive Cancer Center
ORCID: 0000-0001-6906-3796
Observed ORCID: 0000-0001-6906-3796
OpenAlex ID: A5067311792
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer
2023 · Cecilia Monge, Changqing Xie, et al. · Journal for ImmunoTherapy of Cancer · 77
PDF
The current landscape of therapies for hepatocellular carcinoma
2023 · Kelley Coffman-D’Annibale, Changqing Xie, et al. · Carcinogenesis · 32
PDF
A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).
2023 · Changqing Xie, M. Cecilia Monge B., et al. · Journal of Clinical Oncology · 21
Treatment Response and Clinical Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors to Lutetium-177-DOTATATE
2022 · Nitya Raj, Kelley Coffman, et al. · Neuroendocrinology · 18
VB-111 (ofranergene obadenovec) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single center, single arm, phase II trial
2024 · Kelley Coffman-D'Annibale, Yuta Myojin, et al. · Journal for ImmunoTherapy of Cancer · 14
PDF
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma
2024 · Cecilia Monge, Changqing Xie, et al. · Cancer Medicine · 13
PDF
Altering the gut microbiome and tumor microenvironment in advanced liver cancer: A phase II study of nivolumab, tadalafil and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers
2025 · Chi Ma, Joy A. Awosika, et al. · Cancer Letters · 11
IVIG – A cure to severe refractory NAP-1 Clostridium difficile colitis? A case of successful treatment of severe infection, which failed standard therapy including fecal microbiota transplants and fidaxomicin
2017 · Kelley Coffman, Xian Jie Cindy Chen, et al. · IDCases · 9
PDF
Top advances of the year: Hepatobiliary cancers
2023 · Kelley L. Coffman‐D’Annibale, Tim F. Greten · Cancer · 6
PDF
Altering the gut microbiome and TME in advanced liver cancers: A phase II study of nivolumab, tadalafil, and oral vancomycin in refractory HCC or liver-dominant metastatic CRC or PDAC.
2024 · Kelley Coffman D'Annibale, Chi Ma, et al. · Journal of Clinical Oncology · 2
Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.
2023 · M. Cecilia Monge B., Kelley Lauren Coffman, et al. · Journal of Clinical Oncology · 2
Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE.
2021 · Kelley Lauren Coffman, Lisa Bodei, et al. · Journal of Clinical Oncology · 1
Effects of yttrium-90 radioembolization on epigenomic immune remodeling in hepatocellular carcinoma: Profiled by blood-based 3D genome conformation assay.
2026 · Nariman Nezami, Kelley L. Coffman D’Annibale, et al. · Journal of Clinical Oncology
585 Ofranergene obadenovec (VB-111) in combination with nivolumab in patients with microsatellite stable colorectal liver metastases: a single-center, single-arm phase II trial
2023 · Kelley Coffman, Yuta Myojin, et al. · Journal for ImmunoTherapy of Cancer
PDF
A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers.
2023 · Kelley Lauren Coffman, Changqing Xie, et al. · Journal of Clinical Oncology
PDF
Abstract 5465: Immune cell dynamics of patients and mice with hepatocellular carcinoma treated with anti-PD-L1 plus anti-CTLA-4 combination therapy
2023 · Yuta Myojin, Benjamin Ruf, et al. · Cancer Research
The Waverly Gallery
2019 · Kelley L. Coffman · Journal of Palliative Medicine
Simulation Training in a Limited Resource Setting: Teaching Medical Residents in Brazil about Rapid Response Teams
2017 · K. Coffman, D. Rudym, et al. · Annals of Global Health
Works count: 18
Citation count: 206
H-index: 8
I10-index: 7
Year
Topic
Type